Scilex Holding Company (SCLX) Stock

Scilex Holding Company (SCLX) is a Healthcare stock trading at $5.66 (as of 2026-08-21), with a market capitalization of $48.07M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing prescription products for pain treatment. Its commercial product is ZTlido 1.8% (topical lidocaine for neuropathic pain related to post-herpetic neuralgia), and its pipeline includes SP-102 for epidural injections and SP-103 and SP-104 in clinical development for additional pain indications.

Understand Scilex Holding Company: how it makes money

Scilex Holding Company develops and commercializes non-opioid treatments for acute and chronic pain, selling its prescription lidocaine topical product ZTlido 1.8% for neuropathic pain after shingles, and advancing additional candidates (SP-102 in Phase III and SP-103 in Phase II) for later commercialization.

Near-term results depend on ZTlido sales from an already commercial product, while longer-term profit potential hinges on whether SP-102 and SP-103 progress successfully through their clinical trials and reach commercialization.

Business quality (Weak): Clear product and pipeline focus, but the provided dataset includes no reportable segments or operating KPIs, limiting how precisely investors can track day-to-day business drivers.

Bull case

  • Commercial product with a defined pain indication: ZtLido 1.8% is a prescription lidocaine topical product for neuropathic pain related with post-herpetic neuralgia (post-shingles nerve pain).
  • Pipeline progress could expand the profit base: SP-102 is in a Phase III clinical trial for lumbosacral radicular pain, and SP-103 is in a Phase II clinical trial.

Bear case

  • Clinical and development risk: SP-102 and SP-103 are still in clinical trials, so outcomes are uncertain until results support progression.
  • Operating losses suggest limited near-term profitability: For the quarter ended 2026-03-31, the reported operating margin was -373.5%, indicating an operating loss in the period.
Valuation — source: SEC EDGAR (first-party)
Price$5.66
Market Cap$48.07M
Price / Sales1.36
FCF Yield-17.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$30.25M
Net Margin-1236.4%
Revenue Growth (YoY)-46.5%
EPS Growth (YoY)6414.3%
FCF Growth (YoY)-81.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-8.00 (distress)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($3.60M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOHenry H. Ji
Employees115
CountryUS
IPO Date2021-03-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Champions Oncology, Inc. (CSBR)
  • Cardiff Oncology, Inc. (CRDF)
  • eXoZymes, Inc. (EXOZ)
  • INmune Bio, Inc. (INMB)
  • ImageneBio Inc (IMA)
  • MiNK Therapeutics, Inc. (INKT)
  • Instil Bio, Inc. (TIL)
  • Metagenomi, Inc. Common Stock (MGX)
SCLX earnings history · SCLX institutional & insider holders · SCLX KPIs & operating metrics · SCLX financials · SCLX investor presentations & press releases · SCLX SEC filings · SCLX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.